



CANALOPATHIES



Victor WALDMANN

Hôpital Européen Georges Pompidou — Hôpital Necker



IVF: Idiopathic Ventricular Fibrillation

Symptômes


Syncope / Noyade / Comitialité

Circonstances

Effort / Emotion / Fièvre

Famille


**Histoire familiale de mort subite
—
Surdité congénitale**



CARDIAQUES

- **Bradycardies**
Dysfonction sinusale, BAV
- **Tachycardies**
Ventriculaire >> supraventriculaire
- « **Mécaniques** »
Sténose aortique, EP, CMH...

TDR VENTRICULAIRE VS. SYNCOPÉ VAGALE





LES CANALOPATHIES

A


ECG



Action potential



B



TV malgré B-bloquants
Syncope




PHYSIOPATH

17 gènes connus – 1/2500
Mutation identifiée dans 75%:
LQTS1 KCNQ1 (effort ++, natation)
LQTS2 KNCH2 (émotion ou bruit)
LQTS3 SCN5A (repos ou sommeil)
Autosomique dominant (95%)



PRONOSTIC

Taux mort subite annuel 0.3-0.9%
5% par an si antécédent de syncope
LQT3 et QTc > 500 ms à haut risque




« Short-long-short »

QT LONG

PERSPECTIVES

Dénervation
Flecaine ou mexiletine LQTS3
Stratification guidée par génétique




DIAGNOSTIC

QTc ≥ 480 ms
Score > 3
Mutation positive
QTc > 460 ms + syncope inexpliquée



Variable	Points
Electrocardiogram	
QTc ms* ≥480	3
460-470	2
450 (males)	1
Torsade de pointes	2
T wave alternans	1
T wave notches in 3 leads	1
Bradycardia†	0.5
Clinical history	
Syncope	
With stress	2
Without stress	1
Congenital deafness	0.5
Family history†	
Family members with confirmed LQTS§	1
Unexplained sudden death in first-order family members <30 years	0.5




Bazett

$$QTc \text{ interval} = \frac{QT \text{ interval}}{\sqrt{RR \text{ interval}}}$$

D2 ++ ou V5


PRISE EN CHARGE

Médicaments contre indiqués
B-bloquants ++ (Ila pour porteur sain)
Restriction sportive
Dépistage familial
Orage rythmique: +/- SEES




<https://crediblemeds.org/>



QT LONG




ECG allongé : QTc 440ms

ECG debout : QTc 470ms





ECG de base



4^{ème} mn de récupération





FIGURE 2 5-Year Risk of Life-Threatening Arrhythmic Events by Genotype for Each 10-ms Increment of QTc Duration for Patients Who Are Not Receiving Beta-Blockers

5-year risk of Life-Threatening Arrhythmias			
Baseline QTc Interval (ms)	LQT1	LQT2	LQT3
461 – 470	5-YEAR RISK <3%	5-YEAR RISK BETWEEN 3% AND 6%	5-YEAR RISK >9%
471 – 480			
481 – 490			
491 – 500			
501 – 510	5-YEAR RISK BETWEEN 3% AND 6%	5-YEAR RISK BETWEEN 6% AND 9%	5-YEAR RISK >9%
511 – 520			
521 – 530			
531 – 540			
541 – 550	5-YEAR RISK BETWEEN 3% AND 6%	5-YEAR RISK >9%	5-YEAR RISK >9%
551 – 560			
> 560			

Visualization of the 5-year relative risk for patients with each genotype and for each QTc duration. The 4 colors group patients within the same 5-year risk of life-threatening arrhythmic events. This scheme can be used to personalize the risk estimate of patients at diagnosis in the absence of beta-blocker therapy and to estimate the risk of life-threatening arrhythmic events in patients who are not compliant with treatment. QTc = corrected QT interval.


CENTRAL ILLUSTRATION 5-Year Risk of LAEs by Genotype and QTc Interval Before Therapy and Effect of BBs





PHYSIOPATH

Anomalie canaux sodiques
Prévalence 20 / 100 000
Mutation 20% (SCN5A ++, CACN1Ac)
Autosomique dominant
Pénétrance variable, H >> F



PRONOSTIC

Taux mort subite annuel $\rightarrow$ 1% si type 1 spontané
 $\rightarrow$ 3% si syncope
 $\rightarrow$ 10% si ACR
 Type 1 induit de meilleur pronostic



DAI PREVENTION laire



TV soutenue
Syncope rythmique



BRUGADA

DIAGNOSTIC

Type 1 ≥ 2 mm dans 1 dérivation
V1 ou V2 + dérivationes hautes (2-3 EIC)
+/- ajmaline (1 mg/kg IV 5-10 min)




PRISE EN CHARGE

Médicaments contre indiqués
Traitement précoce fièvre
Eviter repas copieux ou alcool excessif
Restriction sportive
Dépistage familial
Orage rythmique: isuprel +/- quinidine



BrugadaDrugs.org

Safe drug use and the Brugada syndrome



PERSPECTIVES


SVP controversée
Place de la quinidine
Indications élargies S-ICD ?
Ablations ?
(substrat épicaudique VD)



Temp. 41°C

Temp. 39°C

Temp. 37°C







Class I_A I_C

*ajmaline
flecainide
procainamide*



**Test pharmaco après 15 ans ++
ou si morts subites pédiatriques**





Asymptomatic AND drug-induced type 1 ECG pattern → LOW RISK


Others clinical situations

→ Intermediate risk ?

Symptoms AND Spontaneous type 1 ECG pattern → HIGH RISK


$n=106$	months	0	12	24	60	96	120
S+/E+ = Sympto. & Spont. Type 1		14	6	6	6	3	2
S+/E- = Sympto. & Drug induced		7	5	5	4	3	2
S-/E+ = Asympto. & Spont. Type 1		22	22	13	11	6	3
S-/E- = Asympto. & Drug induced		63	63	63	63	63	63

Symptoms by age cluster in Brugada syndrome



N = 1057 patients - 269 events


Figure 4. Relative percentage of symptomatic Brugada syndrome patients by age clusters showing a peak of incidence in the third and fourth decades of life (data from the Pavia Brugada syndrome registry).



Management of the Young with a known BrS in the Family

PHYSIOPATH

RyR2 ++ AD
CASQ2 AR
Mutation ~ 60%
Trigger effort/émotion ++



PRONOSTIC

1^{ères} manifestations 10-20 ans

Mort subite à 8 ans $\begin{cases} 11\% \text{ sous B-bloquants} \\ 25\% \text{ sans traitement} \end{cases}$

DIAGNOSTIC


TV polymorphes
TV bidirectionnelles
Bilan morpho normal
Epreuve d'effort ++
Holter
Génétique



CPVT

PRISE EN CHARGE

B-bloquants ++ (IIa pour porteur sain)
+/- Flecaïne
Restriction sportive
Dépistage familial



DAI PREVENTION laire


TV ou syncope sous B-bloquants


Programmation DAI $\begin{cases} \text{zones hautes} \\ \text{longue détection} \end{cases}$
Choc = stim Σ



PERSPECTIVES

Dénervation
Verapamil
Test adrénaline
Ablation
Thérapie génique










REPOLARISATION PRECOCE

PHYSIOPATH

??? H>F
Influence vagale
Génétique mal élucidée
Overlap Brugada
Pattern = 5% popu générale !



DIAGNOSTIC

Sus dec point J ≥ 1 mm dans 2 dérivation
contiguës en inférieur ou latéral
+
TV polymorphe ou FV

PRISE EN CHARGE


Isuprel orage rythmique
+/- Quinidine prévention II^aire

DAI PREVENTION I^aire

A priori pas d'indication
A discuter ++ centre expert (IIb)
(histoire familiale, syncope, pattern à risque)

>2mm
ST horizontal ou descendant

QT COURT



5 gènes mais mutation 20%
Overlap gènes LQTS et Brugada
40% de mort subite à 40 ans

QTc ≤ 340
QTc ≤ 360 +:
Mutation



Histoire famille SQTs ou SCD < 40 ans
TV/FV idiopathique




Quidine ? Sotalol ?
Si refus ou CI de DAI ou mort subite familiale (IIb)

TV soutenue
Histoire familiale SCD ? (IIb)




Eliminer cause 2^aire:
hyperCa, hyperK, acidose, tachycardie, catécholamines...

REPOLARISATION PRECOCE

Notching




Slurring



**ST horizontal ou descendant
= mauvais pronostic**

DIAGNOSTIC




PHYSIOPATH

???

ESV du Purkinje

5% ACR



FV IDIOPATHIQUE

PRISE EN CHARGE

Bilan étiologique exhaustif ++

Prise en charge psychologique

DAI en prévention II^a

Enquête familiale:

Approach	Action*
History taking and physical examination	- Personal clinical history - Family history focused on cardiac diseases or sudden deaths
ECG	- Baseline 12-lead ECG with standard and high precordial leads 24-hour ambulatory ECG - Exercise stress test - Signal-averaged ECG - Provocative test with ajmaline/flecainide (when Brugada syndrome is suspected)
Cardiac imaging	Two-dimensional echocardiography and/or CMR (with or without contrast)
Genetic testing	- Targeted molecular testing and genetic counselling if there is the clinical suspicion of a specific disease - Referral to a tertiary centre specialized in evaluation of the genetics of arrhythmias

PRONOSTIC

Risque de récurrence significatif

20% à 4 ans registre francilien

ESC
European Society
of Cardiology

European Heart Journal (2018) 00, 1-9
doi:10.1093/eurheartj/ehy098

CLINICAL RESEARCH
Arrhythmia/electrophysiology


Characteristics and clinical assessment
of unexplained sudden cardiac arrest in the
real-world setting: focus on idiopathic
ventricular fibrillation

PERSPECTIVES

Nouveaux phénotypes ?

Ablation ESV initiatrice

Rotors






Table 2 Medical investigations of cases labelled idiopathic ventricular fibrillation (performed during the index hospitalization following the sudden cardiac arrest or planned subsequently after discharge)

	IVFs (n = 49), n (%)
Coronary angiography	47 (95.9)
Cardiac MRI	40 (81.6)
Provocative testing	
Ergonovine	19 (38.8)
Ajmaline	21 (42.9)
Isoprenaline	10 (20.4)
Adenosine	2 (4.1)
Adrenaline	0 (0)
Electrophysiological study	12 (24.5)
Genetic testing	9 (18.4)
Holter-ECG	6 (12.2)
Right ventricular angiography	5 (10.2)
Exercise testing	4 (8.2)
Signal averaged ECG	2 (4.1)
Coronary CT	1 (2.0)
Cardiac scintigraphy (for ARVC)	1 (2.0)
Cardiac biopsy	0 (0)



PHYSIOPATH

17 gènes connus – 1/2500
Mutation identifiée dans 75%:
LQTS1 KCNQ1 (effort ++, natation)
LQTS2 KCNH2 (émotion ou bruit)
LQTS3 SCN5A (repos ou sommeil)
Autosomique dominant (95%)

DIAGNOSTIC

QTc ≥ 480 ms
Score > 3
Mutation positive
QTc > 460 ms + syncope inexpliquée

Item	Ponts
Electrocardiogram	3
QTc ≥ 480 ms	2
QTc ≥ 470 ms	1
Trouvée de points	2
T wave abnormal	1
T wave notches in 3 leads	1
Bradycardia	1
Clinical history	1
Syncope	2
Without stress	1
Compromised autonomic	1
Family history	1
Family members with confirmed LQTS	1
Unexplained sudden death in first-order family members < 40 years	1


Bazett

$$QTc \text{ interval} = \frac{QT \text{ interval}}{\sqrt{RR \text{ interval}}}$$

D2 ++ ou V5

PRONOSTIC

Taux mort subite annuel 0.3-0.9%
5% par an si antécédent de syncope
LQTS et QTc > 500 ms à haut risque



« Short-long-short »


QT LONG

PERSPECTIVES

Dénervation
Flecaine ou mexilétine LQTS3
Stratification guidée par génétique

PRISE EN CHARGE

Médicaments contre indiqués
B-bloquants ++ (IIa pour porteur sain)
Restriction sportive
Dépistage familial
Orage rythmique: isuprel +/- SEES



DAI PREVENTION laire

TV malgré B-bloquants
Syncope




PHYSIOPATH

Anomalie canaux sodiques
Mutation 20% (SCN5A ++, CACN1A6)
Autosomique dominant
Pénétrance variable, H $>>$ F

DIAGNOSTIC

Type 1 ≥ 2 mm dans 1 dérivation
V1 ou V2 + dérivations hautes (2-3 EIC)
+/- ajmaline (1 mg/kg IV 5-10 min)




PRONOSTIC

Taux mort subite annuel $\rightarrow$ 1% si type 1 spontané
3% si syncope
10% si ACR
Type 1 induit de meilleur pronostic

BRUGADA

PRISE EN CHARGE


Médicaments contre indiqués
Traitement précoce fièvre
Eviter repas copieux ou alcool excessif
Restriction sportive
Dépistage familial
Orage rythmique: isuprel +/- quinidine



BrugadaDrugs.org

PERSPECTIVES

SVP controversée
Place de la quinidine
Indications élargies S-ICD ?
Ablations ?
(substrat épicaudique VD)




DAI PREVENTION laire

TV soutenue
Syncope rythmique



PHYSIOPATH

RyR2 ++ AD
CASQ2 AR
Mutation ~ 60%
Trigger effort/émotion ++



CPVT


DIAGNOSTIC

TV polymorphes
TV bidirectionnelles
Bilan morpho normal
Epreuve d'effort ++
Holter
Génétique



PRISE EN CHARGE

B-bloquants ++ (IIa pour porteur sain)
+/- Flecaine
Restriction sportive
Dépistage familial



PRONOSTIC

1ères manifestations 10-20 ans
Mort subite à 8 ans $\rightarrow$ 11% sous B-bloquants
25% sans traitement

DAI PREVENTION laire

TV ou syncope sous B-bloquants

Programmation DAI $\rightarrow$ zones hautes
Choc = stim Σ longue détection



PERSPECTIVES

Dénervation
Verapamil
Test adrenaline
Ablation
Thérapie génique



REPOLARISATION PRECOCE

PHYSIOPATH

??? H $>$ F
Influence vagale
Génétique mal élucidée
Overlap Brugada
Pattern = 5% popu générale !

DIAGNOSTIC

Sus dec point J ≥ 1 mm dans 2 dérivation
contiguës en inférieure ou latéral
+
TV polymorphe ou FV


PRISE EN CHARGE

Isuprel orage rythmique
+/- Quinidine prévention IIa

DAI PREVENTION laire

A priori pas d'indication
A discuter ++ centre expert (IIb)
(histoire familiale, syncope, pattern à risque)

> 2 mm
ST horizontal ou descendant



QT COURT

5 gènes mais mutation 20%
Overlap gènes LQTS et Brugada
40% de mort subite à 40 ans

QTc ≤ 340
QTc ≤ 360 +:
Mutation

Histoire famille SQTS ou SCD < 40 ans
TV/FV idiopathique

Quinidine ? Sotalol ?
Si refus ou CI de DAI ou mort subite familiale (IIb)

TV soutenue
Histoire familiale SCD ? (IIb)



Eliminer cause 2aire:
hyperCa, hyperK, acidose, tachycardie, catécholamines

Merci pour votre attention !

Victor WALDMANN

Hôpital Européen Georges Pompidou — Hôpital Necker

victor.waldmann@gmail.com

06 76 09 80 07

01 56 09 37 84